secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adicet Bio, Inc. (ACET)
CIK:        0001720580
Form:       8-K
Filed at:   2026-09-01T11:02:02+00:00
Accession:  0001720580-26-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adicet completes prula-cel SLE study visits; topline due Sept 2026; ADI-212 IND cleared
--------------------------------------------------------------------------------

- Prula-cel Phase 1 last patient visit completed; topline data from 22 SLE patients (13 with ≥12 mo follow-up) expected September 2026.
- FDA cleared IND for ADI-212 in mCRPC; Phase 1 enrollment to start 4Q 2026.
- Expanded prula-cel to outpatient setting after FDA alignment; systemic sclerosis update expected Q4 2026.
- In vivo CAR-T platform: first candidate expected in clinic 2H 2027; programs target myeloma, NHL, solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/0001720580-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/acet-20260901.htm
  HTML page:      https://secwatch.observer/filing/0001720580-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer